Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II

/PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III...

Related Keywords

United States ,Switzerland ,Amos Etzioni ,Bugra Basat ,Drug Administration ,Orpha Labs ,Leukocyte Adhesion Deficiency Type ,Alp Bugra Basat ,Chief Executive Officer ,Professor Emeritus ,Rappaport Faculty ,Scientific Advisory Board ,Rare Pediatric Disease Designation ,New Drug Application ,Priority Review Voucher ,Orphan Drug Designation ,Current Good Manufacturing Practice ,Fucose Transporter ,Orpha Labs Ag ,